Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 2Gliosarcoma 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pain 1Oligodendroglioma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Glioma 1Carcinoma, Renal Cell 1Astrocytoma 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × tandutinib × Clear all
NCT00390468 2014-05-28

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

National Cancer Institute (NCI)

Phase 2 Completed
18 enrolled 5 charts
Genitourinary

Neoplasm Metastasis, Pain, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡